GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- B7387 TCS OX2 29Summary: OX2 receptor antagonist
- B7405 S 25585Summary: neuropeptide Y (NPY) Y5 receptor antagonist
- B7413 ML 10302 hydrochlorideSummary: 5-HT4 partial agonist
- B7427 LU AA33810Summary: neuropeptide Y (NPY) Y5 receptor antagonist
- B7432 SB 657510Summary: urotensin-II (UT) receptor antagonist
- B7433 SB 612111 hydrochlorideSummary: NOP receptor antagonist
- B7435 (±)-5'-Chloro-5'-deoxy-ENBASummary: adenosine A1 receptor agonist, selective and high-affinity
- B7437 Org 12962 hydrochlorideSummary: 5-HT2C receptor agonist
- B7441 CYM 5442Summary: S1P1 agonist, potent and selective
- B7453 FR 171113Summary: Protease-activated receptor 1 (PAR1) antagonist